Diabetes Patents (Class 514/6.9)
  • Patent number: 11981910
    Abstract: Described are DNA molecules which can be transcribed into an mRNA harbouring novel UTR sequences combining the advantages of being extremely short and at the same time allowing for high translation efficiencies of RNA molecules containing them. Further, described are vectors comprising such a DNA molecule and to host cells comprising such a vector. Moreover, described are corresponding RNA molecules containing such UTRs. Further, described is a pharmaceutical composition comprising the described RNA molecule and optionally a pharmaceutically acceptable carrier as well as to the use of the described UTRs for translating a coding region of an RNA molecule into a polypeptide or a protein encoded by said coding region.
    Type: Grant
    Filed: June 6, 2022
    Date of Patent: May 14, 2024
    Assignee: ethris GmbH
    Inventors: Christian Plank, Carsten Rudolph, Manish Kumar Aneja, Ludwig Weiss
  • Patent number: 11975041
    Abstract: A composition containing cyclo-hispro (CHP) and its use in preventing, alleviating, or treating bone loss diseases are disclosed. The composition contains CHP or a CHP-containing prostate extract.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: May 7, 2024
    Assignee: NovMetaPharma Co., Ltd.
    Inventors: Hoe Yune Jung, Heon Jong Lee, Do Hyun Lee
  • Patent number: 11934931
    Abstract: In an embodiment, a computer-implemented method for training a decision tree using a database system, the decision tree comprising a plurality nodes, comprises, by one or more computing devices: storing in a database input data for training the decision tree, the input data comprising a plurality of feature values corresponding to a plurality of features; generating a particular node of the plurality of decision nodes by: selecting a subset of the plurality of features and a subset of the input data; using one or more queries to the database system, for each feature of the subset of the plurality of features, calculating an information gain associated with the feature based on the subset of the input data; identifying a particular feature of the subset of the plurality of features associated with the highest information gain; associating the particular node with the particular feature, wherein the particular node causes the decision tree to branch based on the particular feature.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: March 19, 2024
    Assignee: SHAPE SECURITY, INC.
    Inventors: Bei Zhang, Samir Shah, Kenton Miller
  • Patent number: 11919935
    Abstract: The present disclosure provides recombinantly manufactured ultra-long acting insulin-Fc fusion proteins for use in treating canine diabetes. The insulin-Fc fusion proteins comprise an insulin polypeptide linked via a peptide linker to an Fc-fragment of canine origin. Based on the results obtained, creating a treatment that is amenable to low cost manufacturing, exhibits sufficient in vivo bioactivity, displays extended duration of bioactivity, does not induce anti-drug antibodies, and substantially retains is potency over multiple administrations, requires a non-obvious combination of insulin polypeptide, peptide linkers, and species-specific Fc fragment, in addition to selective mutations on one or more of these components. Exemplary ultra-long acting insulin-Fc fusion proteins, polynucleotides encoding these insulin-Fc fusion proteins, and pharmaceutical formulations of exemplary insulin-Fc fusion proteins are provided, in addition to methods of use and preparation.
    Type: Grant
    Filed: November 10, 2021
    Date of Patent: March 5, 2024
    Assignee: Akston Biosciences Corporation
    Inventors: Thomas M. Lancaster, Todd C. Zion
  • Patent number: 11905319
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: February 20, 2024
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Valentina Goldfinger, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 11890324
    Abstract: A calcitonin gene-related peptide (CGRP) compound can be selected from N-alpha-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxyheptadecanoylamino)-butyrylamino]ethoxy}ethoxy)acetyl][Ser1]alpha-human CGRP peptide (?-CGRP-analogue), or derivatives thereof; or N-alpha-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butyryl-amino]-ethoxy}ethoxy)acetyl][Ser1]beta-human CGRP peptide (?-CGRP-analogue), or derivatives thereof. The CGRP compound can be used to induce myocardial perfusion recovery, in connection with AMI, by activating any CGRP family of receptors with a larger CGRP compound: CGRP potency ratio in the coronary artery than in the mesenteric artery.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: February 6, 2024
    Assignee: Epoqe Pharma ApS
    Inventors: Anette Sams Nielsen, Lars Ingvar Herbert Edvinsson
  • Patent number: 11834518
    Abstract: The invention relates to interference peptides as inhibitors of the interactions related to AMPA receptor endocytosis, to peptide compounds comprising said peptides that can be used in medicine, in the field of neurology and psychiatry, in particular for the prevention and therapy of mild cognitive impairment in neurodegenerative diseases or in the prophylaxis of depression and anxiety, as well as to peptidomimetic compounds of interference peptides with a blocking effect on the interaction between AMPA receptor and STEP phosphatase and to a method of inhibiting AMPA receptor endocytosis in neurons, especially in synaptic neurons.
    Type: Grant
    Filed: January 5, 2023
    Date of Patent: December 5, 2023
    Inventors: Stefan Eugen Szedlacsek, Rodica-Aura Badea, Horea-Stefan Szedlacsek
  • Patent number: 11827905
    Abstract: Disclosed herein are methods, compositions, kits, and agents useful for inducing ? cell maturation, and isolated populations of SC-? cells for use in various applications, such as cell therapy.
    Type: Grant
    Filed: November 1, 2022
    Date of Patent: November 28, 2023
    Assignee: President and Fellows of Harvard College
    Inventors: Quinn P. Peterson, Felicia J. Pagliuca, Douglas A. Melton, Jeffrey Robert Millman, Michael Saris Segel, Mads Gurtler
  • Patent number: 11827698
    Abstract: Provided herein are proteins, antibodies, assays and methods useful for modulating growth factor levels and/or activities. In some embodiments, such growth factors are members of the TGF-? superfamily of proteins.
    Type: Grant
    Filed: March 9, 2021
    Date of Patent: November 28, 2023
    Assignee: Scholar Rock, Inc.
    Inventors: Thomas Schurpf, Nagesh K. Mahanthappa, Michelle Straub
  • Patent number: 11771678
    Abstract: [Object] To clarify the mechanism associated with neuropathy in methylmalonic acidemia and to develop a new therapeutic drug or the like for neuropathy in organic acidemia on the basis of this finding. [Solving Means] The inventors established technologies for the establishment of iPS cells derived from a methylmalonic acidemia patient and establishment of a stable maintenance and culturing method using peripheral blood lymphocytes of a methylmalonic acidemia patient, and for the differentiation of methylmalonic acidemia patient-derived iPS cells into nerve cells. The inventors made clear that neuropathy in organic acidemia can be treated and prevented by replenishing cAMP using a series of these experiment technologies. The drug of the invention treats or prevents neuropathy by increasing cAMP in organic acidemia.
    Type: Grant
    Filed: March 11, 2021
    Date of Patent: October 3, 2023
    Assignee: NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY
    Inventors: Shiro Matsumoto, Takumi Era, Fumio Endo
  • Patent number: 11766419
    Abstract: The present invention relates to a method of using Mebeverine as an sEH inhibitor. The present invention also provides a method of treating metabolic and cardiovascular disorders using Mebeverine.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: September 26, 2023
    Assignee: Banasthali Vidyapith
    Inventors: Sarvesh Paliwal, Swapnil Sharma, Neetika Tripathi, Kanika Verma, Swati Paliwal
  • Patent number: 11766420
    Abstract: The use of a genetic method to down-regulate RBO/EFR3/EFR3A/EFR3B proteins, TTC7 protein or PI4KIII? enzyme protein which interacts with RBO/EFR3/EFR3A/EFR3B proteins and TTC7 protein, or the use of a drug to inhibit PI4KIII? protein kinase activity reduces the accumulation of A?42 within neurons and age-dependent synaptic transmission failure and other obstacles in a fruit fly AD model, and obtains an effect of improving the learning and memory abilities of AD model mice. Provided is a method for using an RBO/EFR3/EFR3A/EFR3B inhibitor, a TTC7 inhibitor and a PI4KIII? inhibitor to treat Alzheimer's disease. Also provided is a method for screening a drug treating Alzheimer's disease by whether A? secretion by nerve cells is promoted or not.
    Type: Grant
    Filed: May 3, 2016
    Date of Patent: September 26, 2023
    Assignee: JIANGSU NUO-BETA PHARMACEUTICAL TECHNOLOGY CO. LTD.
    Inventors: Fude Huang, Xiao Zhang, Wenan Wang, Le Zhang, Lixiang Jiang, Tong Zhu, Haiyan Liu, Yudong Zhou, Yang He, Wanguo Wei
  • Patent number: 11759477
    Abstract: Inorganic anions nitrate and nitrite influence metabolic rate and glucose homeostasis. Infusion of nitrite iv caused an acute drop in resting energy expenditure (oxygen consumption) and nitrate, when given perorally, caused a reduction in oxygen consumption during exercise and a depression of the increase in blood glucose observed after an oral glucose tolerance test. The doses of nitrate and nitrite did not cause any detectable change in methemoglobin levels of blood. Also, nitrate and nitrite did not alter lactate levels in blood. This discovery provides useful treatments to regulate the energy expenditure and glucose homeostasis of a mammal by administration of inorganic nitrite and/or nitrate.
    Type: Grant
    Filed: March 9, 2022
    Date of Patent: September 19, 2023
    Assignee: HEARTBEET LTD.
    Inventors: Jon Lundberg, Eddie Weitzberg
  • Patent number: 11738065
    Abstract: The present invention relates to polypeptides and analogues thereof for use in the treatment of diabetes and bone disorders. Also disclosed are pharmaceutical compositions comprising the polypeptides and analogues thereof, and methods for the treatment of diabetes and bone disorders.
    Type: Grant
    Filed: January 11, 2021
    Date of Patent: August 29, 2023
    Assignee: UNIVERSITY OF ULSTER
    Inventors: Victor Gault, Nigel Irwin
  • Patent number: 11730792
    Abstract: The present invention relates to methods of treating or preventing AIBD.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: August 22, 2023
    Assignee: Volution Immuno Pharmaceuticals SA
    Inventors: Miles Andrew Nunn, Brihad Abhyankar, Christian David Sadik
  • Patent number: 11723946
    Abstract: Methods for regulating multiple organs, multiple genes and multiple targets by using a polypeptide. The polypeptide includes the amino acid sequence of SEQ ID No. 1 and/or homology thereof. The polypeptide reveals the potency to regulate transcription of multiple genes and expression of multiple targets. Therefore, a composition having the polypeptide can be applied to regulate the expression of multiple targets in multiple organs of patients. Furthermore, the composition having the polypeptide can be applied in therapies of inflammation and inflammatory disorders, suppression of fatty liver disease progression, suppression of the diseases caused by fatty accumulation, prevention and therapy of muscular atrophy, and avoiding the complications of diabetes.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: August 15, 2023
    Assignee: CHINA MEDICAL UNIVERSITY
    Inventors: Tin-Yun Ho, Chien-Yun Hsiang
  • Patent number: 11723945
    Abstract: Methods for treating psychiatric and psychological diseases or conditions, including depression, by use of L-tryptophan or a derivative or analog thereof and a derivative of phyllokinin are described. The methods can be used together with other agents for treatment of depression or other psychiatric or psychological diseases or conditions. Pharmaceutical compositions comprising at least one of L-tryptophan or a derivative or analog thereof and a derivative of phyllokinin together with a pharmaceutically acceptable excipient are also described. The pharmaceutical compositions can include other therapeutically active agents for the treatment of psychiatric or psychological diseases or conditions such as depression.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: August 15, 2023
    Inventor: Chris W. Mahne
  • Patent number: 11696935
    Abstract: The present invention provides phosphorylcholine conjugates and pharmaceutical compositions comprising same for the prevention or treatment of autoimmune diseases. In particular, the conjugates of the present invention are effective in treating autoimmune diseases associated with pathological inflammation.
    Type: Grant
    Filed: November 23, 2020
    Date of Patent: July 11, 2023
    Assignee: TPCERA LTD.
    Inventors: Yehuda Shoenfeld, Miriam Blank
  • Patent number: 11685791
    Abstract: The present invention relates to an antibody binding specifically to an N-terminal region of lysyl-tRNA synthetase which is exposed on the cell membrane and a use thereof.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: June 27, 2023
    Assignee: Zymedi Co., Ltd.
    Inventors: Sunghoon Kim, Hyunbo Shim, Nam Hoon Kwon, Daeyoung Han
  • Patent number: 11654111
    Abstract: Provided are solid oral/per os formulations that include a single cannabinoid, combination of cannabinoids, cannabis extract and combination of cannabis plant constituents. Also provided are methods of making the formulations, as well as therapeutic applications in the treatment and alleviation of various human disorders and/or conditions.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: May 23, 2023
    Assignees: SATIPHARM AG, GELPELL AG
    Inventors: Hagit Sacks, Tomas Edvinsson
  • Patent number: 11655289
    Abstract: Pharmaceutical compositions containing anti-beta amyloid (A?) antibodies or AD-binding fragments thereof are provided. These pharmaceutical compositions find use in the treatment of abnormal accumulation or deposition of A? in the central nervous system, mild cognitive impairment, and AD-associated disorders such as Alzheimer's disease.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: May 23, 2023
    Assignee: Biogen MA Inc.
    Inventors: Steven Andrew Lantz, Kapil Gupta, Shantanu Sule, Adnan Zunic
  • Patent number: 11643437
    Abstract: An isolated cancer-targeting peptide that includes at least two copies of the amino acid sequence PFLP (SEQ ID NO: 1) or PFLF (SEQ ID NO: 2). Also disclosed is a pharmaceutical composition for treating cancer. The composition contains the isolated cancer-targeting peptide and an anti-cancer agent. Further disclosed is a bispecific anti-cancer antibody that includes the isolated cancer-targeting peptide and an antigen-binding peptide that stimulates T cell activity. Methods are provided for treating cancer by administering the pharmaceutical composition or the bispecific anti-cancer antibody. Further provided is a method for diagnosing cancer by administering a radionuclide-labeled cancer-targeting peptide to an individual and imaging a location of the radionuclide.
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: May 9, 2023
    Assignee: Chang Gung Memorial Hospital
    Inventors: John Yu, Alice Yu, Sheng-Hung Wang
  • Patent number: 11608379
    Abstract: This invention concerns anti-inflammatory agents, compositions, and methods for treating inflammatory disorders.
    Type: Grant
    Filed: November 20, 2020
    Date of Patent: March 21, 2023
    Assignee: The Rockefeller University
    Inventors: Jeffrey V. Ravetch, Andrew Pincetic
  • Patent number: 11590206
    Abstract: The present invention relates to a liquid pharmaceutical composition comprising a peptide of SEQ ID NO.: 2 as an active pharmaceutical ingredient. The composition of the present invention is suitable for medical use in humans, for example in the treatment of disorders of a metabolic syndrome or diabetes or obesity or for reduction of excess food intake.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: February 28, 2023
    Assignee: SANOFI
    Inventors: Marta Venczel, Nino Meyer, Walter Kamm, Norbert Nagel, Bruno Baumgartner
  • Patent number: 11591365
    Abstract: Disclosed here are polypeptides derived from the HD2 domain of human B-cell CLL/lymphoma 9 (BCL9) protein and variants thereof, as well as their use in the diagnosis, prevention, and/or treatment of a disease or disorder. Also disclosed are methods of generating such polypeptides and variants thereof.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: February 28, 2023
    Assignee: WntRx Pharmaceuticals Inc.
    Inventors: David Zhu, Robert Perni, Yvonne Angell
  • Patent number: 11566059
    Abstract: The present invention relates to long-acting insulin analogues having an increased in vivo half-life in which the amino acid at position 22 of the B-chain of native insulin is substituted and one or more amino acids of the A-chain or B-chain of native insulin are additionally substituted, and to long-acting insulin analogue derivatives having a further increased in vivo half-life in which an albumin-binding domain is additionally fused to the long-acting insulin analogues. The insulin analogues or insulin analogue derivatives according to the present invention have a significantly increased in vivo half-life, and thus can provide convenience to diabetic patients who self-administer insulin by injection.
    Type: Grant
    Filed: July 18, 2019
    Date of Patent: January 31, 2023
    Assignee: DAEWOONG PHARMACEUTICAL CO., LTD.
    Inventors: Kyong Hoon Ahn, Oh-Byung Kwon, Seung Woo Kim
  • Patent number: 11529419
    Abstract: There is provide an extended release dosage form comprising a release modifying excipient comprising high amylose starch, cross-linked hydroxypropylated amylopectin, and a pre-gelatinized common starch; wherein the release modifying excipient is substantially free of crosslinks between amylose and amylopectin and substantially free of crosslinks between amylose and amylose. It has been found that the extended release properties of conventional cross-linked high amylose starches (e.g., Contramid®) can be reproduced by intimately mixing i) cross-linked chemically modified amylopectin; ii) a high amylose, non-chemically modified starch and; iii) a pre-gelatinized common starch. Producing a release modifying excipient in this way means that no chemical cross linking between (a) amylose and amylopectin or (b) amylose and amylose has occurred—properties heretofore considered vital for Contramid® function.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: December 20, 2022
    Assignee: ALTUS FORMULATION INC.
    Inventors: Marc Lemieux, Bradut Mitrasca, Sonia Gervais, Damon Smith
  • Patent number: 11521639
    Abstract: The present disclosure describes a system, method, and computer program for predicting sentiment labels for audio speech utterances using an audio speech sentiment classifier pretrained with pseudo sentiment labels. A speech sentiment classifier for audio speech (“a speech sentiment classifier”) is pretrained in an unsupervised manner by leveraging a pseudo labeler previously trained to predict sentiments for text. Specifically, a text-trained pseudo labeler is used to autogenerate pseudo sentiment labels for the audio speech utterances using transcriptions of the utterances, and the speech sentiment classifier is trained to predict the pseudo sentiment labels given corresponding embeddings of the audio speech utterances. The speech sentiment classifier is then subsequently fine tuned using a sentiment-annotated dataset of audio speech utterances, which may be significantly smaller than the unannotated dataset used in the unsupervised pretraining phase.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: December 6, 2022
    Assignee: ASAPP, INC.
    Inventors: Suwon Shon, Pablo Brusco, Jing Pan, Kyu Jeong Han
  • Patent number: 11471533
    Abstract: The present invention provides a compound represented by formula (I) usable as a cationic lipid that facilitates introduction of a nucleic acid, for example, into a cell, and a composition or the like containing the compound.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: October 18, 2022
    Assignee: KYOWA KIRIN CO., LTD.
    Inventors: Shintaro Hosoe, Hayato Yabuuchi
  • Patent number: 11466061
    Abstract: The present invention relates to methods and compositions for treating and/or preventing a disease or disorder associated with abnormally high level of the IFP35 family of proteins, including IFP35 and NMI, methods and compositions for diagnosis, prognosis or treatment monitoring of a disease or disorder associated with abnormally high level of the IFP35 family of proteins, including IFP35 and NMI, and methods and compositions for identifying a modulator of the IFP35 family of proteins, including IFP35 and NMI.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: October 11, 2022
    Inventor: Yingfang Liu
  • Patent number: 11447523
    Abstract: The invention provides a method for treating one or more complications of diabetes in a mammal. The method comprises administering to a mammal in need thereof an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3 pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1.
    Type: Grant
    Filed: April 2, 2020
    Date of Patent: September 20, 2022
    Assignee: CORNELL RESEARCH FOUNDATION, INC.
    Inventors: Hazel H. Szeto, Shaoyi Liu, Sunghee Cho
  • Patent number: 11442058
    Abstract: The present invention relates to a use of leucine-zipper protein for diagnosis or treatment of fatty liver. According to the present invention, it could be confirmed that a particular fragment present at the leucine-zipper protein, especially, the N-terminal region thereof, plays an important role in the lipid metabolism in liver tissue by regulating transcriptional activity of Apolipoprotein A4, and therefore, the protein of the present invention or a fragment thereof can be utilized as a target for diagnosis, prevention, or treatment of fatty liver.
    Type: Grant
    Filed: July 8, 2020
    Date of Patent: September 13, 2022
    Assignee: Korea University Research and Business Foundation
    Inventors: Jesang Ko, Min-Soo Kang
  • Patent number: 11400131
    Abstract: The invention relates to a specific peptide combination. The peptide combination may be present in a pharmaceutically acceptable composition. The peptide combination can be used in the therapy or prevention of Type 1 Diabetes (TID). The invention also relates to a method of diagnosing or determining treatment efficacy, the method utilising the specific peptide combination.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: August 2, 2022
    Assignee: King's College London
    Inventor: Mark Peakman
  • Patent number: 11389476
    Abstract: The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis, comprising at least in part donor apheresis, using gal-3 binding agents in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles. This method, on its own, brings a sharp reduction and relief from the inflammation and fibroses that can be induced by circulating gal-3. The process may be combined with the administration of gal-3 binding agents, such as modified citrus pectin, to further lower unbound gal-3 levels, to the point where gal-3 in the tissues may be addressed. This method may also be combined with removal of TNF receptors to provide an effective treatment for cancer.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: July 19, 2022
    Assignee: ELIAZ THEREAPEUTICS, INC.
    Inventor: Isaac Eliaz
  • Patent number: 11352624
    Abstract: The present disclosure relates to compositions and methods for inhibiting nonsense-mediated mRNA decay in a gene-specific manner, for example in the treatment of diseases or disorders caused by nonsense mutations.
    Type: Grant
    Filed: April 2, 2020
    Date of Patent: June 7, 2022
    Assignee: Cold Spring Harbor Laboratory
    Inventors: Adrian Krainer, Isabel Aznarez, Tomoki Nomakuchi
  • Patent number: 11344614
    Abstract: Dengue Fever (DF) and Dengue Hemorrhagic Fever (DHF) are significant global public health problems and understanding the overall immune response to infection will contribute to appropriate management of the disease and its potentially severe complications. Live attenuated and subunit vaccine candidates, which are under clinical evaluation, induce primarily an antibody response to the virus and minimal cross-reactive T cell responses. Currently, there are no available tools to assess protective T cell responses during infection or post vaccination. Herein, we report novel, naturally processed and presented MHC class I restricted epitopes, a subset of which binds to and activates T cells in both an HLA-A2 and HLA-A24 restricted manner.
    Type: Grant
    Filed: September 29, 2018
    Date of Patent: May 31, 2022
    Assignee: Emergex Vaccines Holding Ltd.
    Inventor: Ramila Philip
  • Patent number: 11311497
    Abstract: Provided are a pharmaceutical composition including geraniol or a pharmaceutically acceptable salt thereof as an active ingredient for use in preventing or treating diabetes mellitus, and a method of preventing or treating diabetes mellitus or a complication due to diabetes mellitus of an individual, in which the method includes administering to the individual a pharmaceutical composition comprising geraniol or a pharmaceutically acceptable salt thereof as an active ingredient and inducing an olfactory stimulation to the individual using the pharmaceutical composition. Also provided is a screening method for an antidiabetic agent that may include contacting a cell expressing an olfactory receptor with a test material; measuring a level of expression of glucagon-like peptide-1 (GLP-1) secreted from the cell; and determining that the test material, when the test material promotes expression of GLP-1, as a candidate material for an antidiabetic agent.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: April 26, 2022
    Inventor: Hyeung Jin Jang
  • Patent number: 11179325
    Abstract: The present invention provides combination therapies for treating a metabolic disorder, such as type 2 diabetes, obesity, and related comorbidities (e.g., NASH or NAFLD)) in an individual undergoing treatment with a gastrointestinal implant. The combination therapies described herein include methods for treating an individual with a gastrointestinal implant with a metabolic agent, a bariatric procedure, and/or a microbiota modulator.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: November 23, 2021
    Assignee: GI Dynamics, Inc.
    Inventor: Scott Schorer
  • Patent number: 11141422
    Abstract: The present invention relates to methods for treating or preventing pulmonary hypertension, reducing mortality in a subject experiencing pulmonary hypertension, or inhibiting ADP-mediated vasoconstriction of pulmonary arteries in a subject, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a reversible P2Y12 receptor antagonist. Also provided are related medicaments, pharmaceutical compositions, and methods for preparing the medicaments.
    Type: Grant
    Filed: April 4, 2019
    Date of Patent: October 12, 2021
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: David Kylhammar, Goran Radegran
  • Patent number: 11078250
    Abstract: The disclosure provides a high-activity long-acting hypoglycemic fusion protein, which is formed by connecting, via a linker peptide or directly, a high-activity Exendin-4 mutant with an optimally mutated Fc fragment of a human immunoglobulin IgG1. The optimally mutated Fc fragment of the human immunoglobulin IgG1 comprises an optimally mutated human IgG1 hinge region and human IgG1 constant regions CH2 and CH3.
    Type: Grant
    Filed: February 16, 2019
    Date of Patent: August 3, 2021
    Assignee: China Pharmaceutical University
    Inventors: Shuhua Tan, Lili Gu, Jian Fu, Yongbo Zhang, Qinghua Tian, Yue Wang, Xiaojian Gong
  • Patent number: 11058748
    Abstract: Stable liquid formulations of GLP-1 and GLP-1 analogues and method of using such formulations in the treatment of disorders or conditions are provided.
    Type: Grant
    Filed: December 2, 2020
    Date of Patent: July 13, 2021
    Assignee: Rose Pharma LLC
    Inventors: Andrea Hawe, Eva Keilhauer, Olimpia Popko, Enda Kenny, Richard Warburg
  • Patent number: 11001620
    Abstract: The present invention relates to a composition for the diagnosis and treatment of recurrent thyroid cancer comprising recombinant human thyroid stimulating hormone (rhTSH) and a method for producing the recombinant human thyroid hormone. The method for producing recombinant human thyroid hormone according to the present invention can effectively produce rhTSH despite being cultured through fed-batch culture, and has a high purification yield and purity. Therefore, the recombinant thyroid stimulating hormone produced by the method can be usefully used for the diagnosis or treatment of recurrent thyroid cancer.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: May 11, 2021
    Assignee: PROGEN CO., LTD.
    Inventors: Young Chul Sung, Zungyoon Yang
  • Patent number: 10961290
    Abstract: Methods for treating cancer with a stabilized BCL9 peptide are encompassed, wherein the stabilized peptide comprises a portion of the HD2 domain of the BCL9 protein containing a hydrocarbon crosslinker generated using ?, ?-disubstituted amino acids.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: March 30, 2021
    Assignee: WntRx Pharmaceuticals Inc.
    Inventor: David Zhu
  • Patent number: 10961578
    Abstract: This invention provides methods of using phagocytic cells alone or in combination with non-phagocytic cells in the diagnosis, prognosis, or monitoring of prenatal or pregnancy-related diseases or conditions. The invention also provides methods of using phagocytic cells alone or in combination with non-phagocytic cells to identify markers of prenatal or pregnancy-related diseases or conditions.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: March 30, 2021
    Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventor: Amin I. Kassis
  • Patent number: 10940182
    Abstract: The present invention is based on the discovery that a VIP having a binding preference for VPAC2 can provide long-acting blood pressure control synergistically with concomitant anti-hypertensive therapies. Accordingly, methods and compositions useful for the treatment and/or amelioration of hypertension are provided.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: March 9, 2021
    Assignee: PHASEBIO PHARMACEUTICALS, INC.
    Inventors: Lynne M. Georgopoulos, Susan Arnold
  • Patent number: 10933117
    Abstract: Provided are methods, agents and kits for use in assessing the effect of treatment on cancer patients. Further provided is a combination therapy for reducing the administered standard of care doses of anti-cancer agents in treated cancer patients.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: March 2, 2021
    Assignee: IMMUNE SYSTEM KEY LTD.
    Inventors: Yoram Devary, Uziel Sandler
  • Patent number: 10836794
    Abstract: The invention relates to the chemistry of peptides, pharmacology and medicine, and specifically to a new group of peptides having the property of stimulating sexual and genital function and having increased storage stability. For this purpose, peptides of general formula (I) are proposed: A-Thr-Lys-Hyp-B-C-D-X, (SEQ ID NO: 8), in which A is 0, Met, Met(0), Thr, Ala, His, Phe, Lys, Gly; B is 0, Gly, Asp, Trp, Gln, Asn, Tyr, Hyp, Arg; C is 0, Arg, Phe, Tyr, Gly, His, Hyp, Lys; D is 0, Val, Gly, Tyr, Trp, Phe, His; X is OH, OCH3, NH2; where 0 is the absence of an amino acid residue, provided that if A?0, then B and/or C and/or D?0, if B?0, then C and/or D?0, excluding the tetrapeptides, as well as the peptides Phe-Thr-Lys-Hyp-Gly, (SEQ ID NO: 9), Thr-Lys-Hyp-Hyp-Arg (SEQ ID NO: 10) and Thr-Lys-Hyp-Arg-Gly (SEQ ID NO: 11).
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: November 17, 2020
    Assignee: “IVIX” LTD.
    Inventors: Nikolai Fedorovich Myasoedov, Lyudmila Alexandrovna Andreeva, Dmitry Viktorovich Golikov, Mikhail Yurievich Lomonosov
  • Patent number: 10729634
    Abstract: Sex hormone-binding globulin and/or any fragment thereof for use as a medicament, in particular for use in the treatment of obesity and hepatic steatosis. The invention also relates to the cosmetic use of the sex hormone-binding globulin and/or any fragment thereof for improving the bodily appearance of a mammal with subcutaneous fat herniated or accumulated within the fibrous connective tissue under the skin, in particular the cosmetic use is for cellulite.
    Type: Grant
    Filed: May 29, 2014
    Date of Patent: August 4, 2020
    Assignee: FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON—INSTITUT DE RECERCA
    Inventors: David Martinez Selva, Rafael Simó Canonge, Cristina Hernández Pascual, Cristina Saez Lopez, Anna Barbosa Desongles
  • Patent number: 10689430
    Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: June 23, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Christina Madsen-Duggan, Yuping Zhu, Ahmet Kekec, Zhicai Wu
  • Patent number: 10610538
    Abstract: The present invention relates to a class of novel pradimicins and analogues and derivatives thereof, including the compounds of formula A, I and 111, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof and their use to treat or prevent kinetoplastid infections and their use to manufacture a medicine to treat or prevent kinetoplastid infections, particularly infections with trypanosoma and leishmania, such as Trypanosoma brucei, Trypanosoma cruzi and Leischmania donovani. wherein Ra, R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the claim 1 or as described in detail in the description of the invention. The present invention also relates to pharmaceutical compositions of said compounds and the use of said pharmaceutical compositions to treat or prevent kinetoplastid infections.
    Type: Grant
    Filed: October 10, 2013
    Date of Patent: April 7, 2020
    Assignees: Katholieke Universiteit Leuven, Consejo Superior de Investigaciones Científicas - CSIC
    Inventors: Jan Balzarini, Dolores González Pacanowska, Luis Miguel Ruiz Pérez, Victor Castillo Acosta, Yasuhiro Igarashi